Kigamicin C

Kigamicin C was discovered by an anti-austerity strategy targeting cancer cells' tolerance to starvation. It selectively kills PANC-1 cells (a pancreatic cell line) at concentrations 100 times lower under nutrient starved conditions than in normal conditions. The mechanism of action is proposed to be via blocking of the activation of PKB/Akt caused by the withdrawal of nutrients. Active in vivo against a human pancreatic cancer xenograft model. Also inhibits the growth of Gram-positive bacteria including Staphylococcus aureus MRSA, but not active against Gram-negative bacteria.\n\nPurity: >95% by HPLC\n\nSolubility: Soluble in ethanol, methanol, DMF or DMSO.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

K1765-25

Size

500ug

Purity

>95% by HPLC

References

1. Kigamicin D, a novel anticancer agent based on a new anti-austerity strategy targeting cancer cells' \ntolerance to nutrient starvation. Lu J. et al. Cancer Sci. 2004, 95, 547. \n2. Kigamicins, novel antitumor antibiotics. II. Structure determination. Kunimoto S. et al. J. Antibiot. 2003, \n56, 1012. \n3. Kigamicins, novel antitumor antibiotics. I. Taxonomy, isolation, physico-chemical properties and \nbiological activities. Kunimoto S. et al. J. Antibiot. 2003, 56, 1004.